Klussmann Jens P, Mooren Jeroen J, Lehnen Martin, Claessen Sandra M H, Stenner Markus, Huebbers Christian U, Weissenborn Soenke J, Wedemeyer Inga, Preuss Simon F, Straetmans Jos M J A A, Manni Johannes J, Hopman Anton H N, Speel Ernst-Jan M
Department of Oto-Rhino-Laryngology, Head and Neck Surgery, Jean-Uhrmacher Institute, University of Cologne, Cologne, Germany.
Clin Cancer Res. 2009 Mar 1;15(5):1779-86. doi: 10.1158/1078-0432.CCR-08-1463. Epub 2009 Feb 17.
Patients with human papillomavirus (HPV)-containing oropharyngeal squamous cell carcinomas (OSCC) have a better prognosis than patients with HPV-negative OSCC. This may be attributed to different genetic pathways promoting cancer.
We used comparative genomic hybridization to identify critical genetic changes in 60 selected OSCC, 28 of which were associated with HPV-16 as determined by HPV-specific PCR and fluorescence in situ hybridization analysis and positive p16(INK4A) immunostaining. The results were correlated with HPV status and clinical data from patients.
Two thirds of OSCC harbored gain at 3q26.3-qter irrespective of HPV status. In HPV-negative tumors this alteration was associated with advanced tumor stage (P=0.013). In comparison with HPV-related OSCC, the HPV-negative tumors harbored: (a) a higher number of chromosomal alterations and amplifications (P=0.03 and 0.039, respectively); (b) significantly more losses at 3p, 5q, 9p, 15q, and 18q, and gains/amplifications at 11q13 (P=0.002, 0.03; <0.001, 0.02, 0.004, and 0.001, respectively); and (c) less often 16q losses and Xp gains (P=0.02 and 0.03). Survival analysis revealed a significantly better disease-free survival for HPV-related OSCC (P=0.02), whereas chromosome amplification was an unfavorable prognostic indicator for disease-free and overall survival (P=0.01 and 0.05, respectively). Interestingly, 16q loss, predominantly identified in HPV-related OSCC, was a strong indicator of favorable outcome (overall survival, P=0.008; disease-free survival, P=0.01) and none of these patients had a tumor recurrence.
Genetic signatures of HPV-related and HPV-unrelated OSCC are different and most likely underlie differences in tumor development and progression. In addition, distinct chromosomal alterations have prognostic significance.
含人乳头瘤病毒(HPV)的口咽鳞状细胞癌(OSCC)患者的预后比HPV阴性的OSCC患者更好。这可能归因于促进癌症发生的不同遗传途径。
我们使用比较基因组杂交技术来鉴定60例选定的OSCC中的关键基因变化,其中28例通过HPV特异性PCR、荧光原位杂交分析以及p16(INK4A)免疫染色呈阳性确定与HPV-16相关。将结果与患者的HPV状态和临床数据相关联。
无论HPV状态如何,三分之二的OSCC在3q26.3 - qter区域存在扩增。在HPV阴性肿瘤中,这种改变与肿瘤晚期相关(P = 0.013)。与HPV相关的OSCC相比,HPV阴性肿瘤具有:(a)更多的染色体改变和扩增(分别为P = 0.03和0.039);(b)在3p、5q、9p、15q和18q区域有明显更多的缺失,以及在11q13区域有扩增(分别为P = 0.002、0.03;<0.001、0.02、0.004和0.001);(c)较少出现16q缺失和Xp扩增(P = 0.02和0.03)。生存分析显示,HPV相关的OSCC无病生存期明显更好(P = 0.02),而染色体扩增是无病生存期和总生存期的不良预后指标(分别为P = 0.01和0.05)。有趣的是,主要在HPV相关的OSCC中发现的16q缺失是良好预后的有力指标(总生存期,P = 0.008;无病生存期,P = 0.01),并且这些患者均无肿瘤复发。
HPV相关和HPV不相关的OSCC的基因特征不同,很可能是肿瘤发生和进展差异的基础。此外,不同的染色体改变具有预后意义。